公司簡介
AItewan BioMedical Technology Inc. was founded by Distinguished Professor Wu Yu-Te of National Yang Ming Chiao Tung University (NYCU), following the execution of two National Science and Technology Council (NSTC) Taiwan Germination Program I and II. These projects focused on the use of artificial intelligence to assist in the automatic annotation of brain tumor MRI images at multiple time points both pre- and post-operation, and on the development of the DeepBT intelligent precision medicine system for brain tumors: lesion detection and annotation over time (Tracker). The company was established with the approval of NYCU's spin-off regulations for AI-based smart healthcare startups, co-founded by Distinguished Professor Wu Yu-Te and Dr. Guo Wan-Yuo.
The brain tumor detection assistance system resulting from these NSTC research projects, known as the DeepBT Detector, has been exclusively licensed to NYCU and Taipei Veterans General Hospital. The DeepBT Detector has received multiple professional awards, including the "2022 Future Tech Award," the "19th National Innovation Award - Academic Research and Innovation Award," and the "National Innovation Advancement Award."
Our company's business philosophy emphasizes the full utilization of AI technology to enhance patient care quality, reduce the workload of physicians, and achieve the goals of fast, objective, quantitative, accurate, and seamless healthcare.
AItewan BioMedical Technology will continue to collaborate with medical institutions such as NYCU, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Wu Huo-Shih Memorial Hospital, and the NYCU Affiliated Hospital. Additionally, the company will form strategic alliances with various information system vendors to assist in promoting and implementing AI technology.